| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c76ecadad74a1a35270b3e3a34d60f37 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0004
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 |
| filingDate |
2003-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_797b810b6146fca1e5ff932b59e0bc7f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0728fadac7202408a2bc3073ad7cd82f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c7283f032fa54a699227d8282a98cc3 |
| publicationDate |
2003-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
PE-20030806-A1 |
| titleOfInvention |
CONTROLLED RELEASE PHARMACEUTICAL DOSAGE FORMS OF A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR |
| abstract |
WHICH INCLUDES: A) AN ENHANCED SOLUBILITY FORM OF A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR (CETPI), WHICH IS ETHYL ACID [1R, 4S] -4 - [(3,5-BISTRIFLUOROMETILBENZYL) METOXYCARBONYLAMIN] - 2-ETHYL-6-TRIFLUOROMETIL-3,4-DIHYDRO-2H-QUINOLIN-1-CARBOXYL; AND, B) A CONTROLLED RELEASE MEANS TO RELEASE CETPI. WHERE, AFTER ADMINISTRATION TO AN IN VIVO USE ENVIRONMENT, THE CITED FORM OF CONTROLLED RELEASE PROVIDES AT LEAST ONE OF THE FOLLOWING: 1) AT LEAST 50% INHIBITION OF CHOLESTERYL ESTER PLASMA TRANSFER PROTEIN DURING AT LEAST 12 HOURS; 2) A MAXIMUM DRUG CONCENTRATION IN THE BLOOD LESS OR EQUAL TO 80% OF THE MAXIMUM DRUG CONCENTRATION IN THE BLOOD PROVIDED BY AN IMMEDIATE RELEASE DOSAGE FORM CONSTITUTED BY THE SAME AMOUNT OF THE POTENTIAL CET SOLUBILITY FORM; iii) AN AVERAGE LEVEL OF HDL CHOLESTEROL AFTER DOSING FOR 8 WEEKS WHICH IS AT LEAST APPROXIMATELY 1.2 TIMES THAT OBTAINED BEFORE DOSING; AND, iv) AN AVERAGE LEVEL OF LDL CHOLESTEROL AFTER DOSING FOR 8 WEEKS THAT IS LESS OR EQUAL TO 90% OF THAT OBTAINED BEFORE DOSING |
| priorityDate |
2002-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |